Cargando…
A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles
SARS-CoV-2 infection is mediated by the interaction of the spike glycoprotein trimer via its receptor-binding domain (RBD) with the host's cellular receptor. Vaccines seek to block this interaction by eliciting neutralizing antibodies, most of which are directed toward the RBD. Many protein sub...
Ejemplares similares
-
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials
por: Eugenia-Toledo-Romaní, María, et al.
Publicado: (2022) -
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults
por: Toledo-Romani, María Eugenia, et al.
Publicado: (2022) -
Molecular Aspects Concerning the Use of the SARS-CoV-2
Receptor Binding Domain as a Target for Preventive Vaccines
por: Valdes-Balbin, Yury, et al.
Publicado: (2021) -
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial
por: Chang-Monteagudo, Arturo, et al.
Publicado: (2021) -
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity
por: Pérez-Rodríguez, Sonia, et al.
Publicado: (2022)